Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Receives $6.88 Consensus PT from Analysts – Defense World

Shares of Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT Get Rating) have been assigned an average recommendation of Buy from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $6.88.

A number of brokerages have issued reports on CRXT. Maxim Group decreased their price objective on Clarus Therapeutics to $1.50 in a research report on Thursday. Zacks Investment Research raised Clarus Therapeutics from a hold rating to a buy rating and set a $1.75 target price on the stock in a research note on Monday, April 4th. Needham & Company LLC dropped their price objective on Clarus Therapeutics to $3.00 and set a buy rating on the stock in a research note on Tuesday, May 17th. Finally, Truist Financial dropped their target price on Clarus Therapeutics from $7.00 to $3.00 and set a na rating on the stock in a research report on Tuesday, May 17th.

A number of hedge funds have recently modified their holdings of CRXT. Verition Fund Management LLC acquired a new stake in Clarus Therapeutics during the 3rd quarter worth about $160,000. UBS Group AG acquired a new stake in Clarus Therapeutics during the 3rd quarter worth about $206,000. Telemetry Investments L.L.C. acquired a new stake in Clarus Therapeutics during the 3rd quarter worth about $240,000. Powell Investment Advisors LLC grew its position in Clarus Therapeutics by 48.8% during the 4th quarter. Powell Investment Advisors LLC now owns 64,000 shares of the companys stock worth $156,000 after purchasing an additional 21,000 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Clarus Therapeutics during the 4th quarter worth about $31,000. Institutional investors own 19.50% of the companys stock.

Clarus Therapeutics (NASDAQ:CRXT Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.61) EPS for the quarter. The company had revenue of $4.01 million during the quarter. On average, equities research analysts anticipate that Clarus Therapeutics will post -1.22 EPS for the current year.

Clarus Therapeutics Company Profile (Get Rating)

Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Further Reading

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original here:
Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Receives $6.88 Consensus PT from Analysts - Defense World